TY - JOUR
T1 - Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer
T2 - a ten-year, monocentric, retrospective study
AU - Vernieri, Claudio
AU - Milano, Monica
AU - Mennitto, Alessia
AU - Maggi, Claudia
AU - Ferrari, Benvenuto
AU - Rinaldi, Lucia
AU - Mennitto, Roberta
AU - Stefanetti, Claudia
AU - Re, Barbara
AU - Mariani, Gabriella
AU - Bianchi, Giulia
AU - Capri, Giuseppe
AU - de Braud, Filippo
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Background: Taxanes are a mainstay in the treatment of metastatic breast cancer (mBC). Combination chemotherapy, including platinum–taxens doublets, can improve tumor responses and progression-free survival (PFS), but is associated with more toxicities and an uncertain benefit in terms of overall survival (OS). Methods: We performed a retrospective study on 274 consecutive patients with mBC treated at the Division of Medical Oncology of Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, during the decade 2007–2016 with the combination of carboplatin AUC 2 plus paclitaxel 80 mg/m2, both given on days 1 and 8 in every 21-day cycle. Results: 264 patients were evaluable for treatment safety and activity. The objective response rate (ORR) was 44.7%. Median PFS and OS were 8.6 and 23.7 months, respectively. Triple-negative breast cancer (TNBC) patients had significantly lower PFS and OS times compared to other biology groups. At multivariable analysis, previous exposure to taxanes, HR-positive HER2-negative biology, a higher number of metastatic sites, and de novo metastatic disease at diagnosis were associated with reduced PFS, while receiving maintenance therapy correlated with improved PFS. Overall, the treatment was quite well tolerated, with 10.2% of patients discontinuing one or both drugs because of adverse events (AEs). G3–G4 neutropenia occurred in 16.8% of patients, while the incidence of febrile neutropenia was 2.3%. Conclusions: Weekly carboplatin–paclitaxel regimen is active and well tolerated in mBC treatment. Prospective studies should be conducted to compare its efficacy and tolerability with standard single-agent paclitaxel or docetaxel treatment schedules, as well as with more recent combination regimens.
AB - Background: Taxanes are a mainstay in the treatment of metastatic breast cancer (mBC). Combination chemotherapy, including platinum–taxens doublets, can improve tumor responses and progression-free survival (PFS), but is associated with more toxicities and an uncertain benefit in terms of overall survival (OS). Methods: We performed a retrospective study on 274 consecutive patients with mBC treated at the Division of Medical Oncology of Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, during the decade 2007–2016 with the combination of carboplatin AUC 2 plus paclitaxel 80 mg/m2, both given on days 1 and 8 in every 21-day cycle. Results: 264 patients were evaluable for treatment safety and activity. The objective response rate (ORR) was 44.7%. Median PFS and OS were 8.6 and 23.7 months, respectively. Triple-negative breast cancer (TNBC) patients had significantly lower PFS and OS times compared to other biology groups. At multivariable analysis, previous exposure to taxanes, HR-positive HER2-negative biology, a higher number of metastatic sites, and de novo metastatic disease at diagnosis were associated with reduced PFS, while receiving maintenance therapy correlated with improved PFS. Overall, the treatment was quite well tolerated, with 10.2% of patients discontinuing one or both drugs because of adverse events (AEs). G3–G4 neutropenia occurred in 16.8% of patients, while the incidence of febrile neutropenia was 2.3%. Conclusions: Weekly carboplatin–paclitaxel regimen is active and well tolerated in mBC treatment. Prospective studies should be conducted to compare its efficacy and tolerability with standard single-agent paclitaxel or docetaxel treatment schedules, as well as with more recent combination regimens.
KW - Combination chemotherapy
KW - HER2-positive breast cancer
KW - Hormone receptor-positive breast cancer
KW - Metastatic breast cancer
KW - Triple-negative breast cancer
KW - Weekly carboplatin–paclitaxel
UR - http://www.scopus.com/inward/record.url?scp=85020733000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020733000&partnerID=8YFLogxK
U2 - 10.1007/s10549-017-4336-z
DO - 10.1007/s10549-017-4336-z
M3 - Article
AN - SCOPUS:85020733000
VL - 165
SP - 365
EP - 373
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 2
ER -